Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Huang, Gea; 1; * | Huang, Qingb; 1 | Xie, Zilub | Zhou, Huihuia | Cao, Jiangboa | Shi, Longb | Yang, Mingweia
Affiliations: [a] Department of Respiratory Medicine, Jingmen No. 2 People’s Hospital, Jingmen, Hubei, China | [b] Department of Utrasound, Jingmen No. 2 People’s Hospital, Jingmen, Hubei, China
Correspondence: [*] Corresponding author: Ge Huang, Department of Respiratory Medicine, Jingmen No. 2 People’s Hospital, No. 39 Xiangshan Road, Jingmen, Hubei 448000, China. Tel./Fax: +86 724 6903017; E-mail: huangge384755413@163.com.
Note: [1] Contributed equally to this work.
Abstract: BACKGROUND: Lung squamous cell carcinoma (LUSC) is malignant disease with poor therapeutic response and unfavourable prognosis. OBJECTIVE: This study aims to develop a long non-coding RNA (lncRNA) signature for survival prediction in patients with LUSC. METHODS: We obtained lncRNA expression profiles of 493 LUSC cases from The Cancer Genome Atlas, and randomly divided the samples into a training set (n= 296) and a testing set (n= 197). Univariate Cox regression and random survival forest algorithm were performed to select optimum survival-related lncRNAs. RESULTS: A lncRNA-focused risk score model was then constructed for prognosis prediction in the training set and further validated in the testing set and the entire set. Finally, bioinformatics analysis was carried out to explore the potential signaling pathways associated with the prognostic lncRNAs. A set of 9 lncRNAs were found to be strongly correlated with overall survival of LUSC patients. These 9 lncRNAs were integrated into a prognostic signature, which could separate patients into high- and low-risk groups with significantly different survival times in the training set (median: 30.5 vs. 80.5 months, log-rank P< 0.001). This signature was also confirmed in the testing set and the entire set. Besides, the prognostic value of the 9-lncRNA signature was independent of clinical features and maintained stable in stratified analyses. Functional enrichment study suggested that the 9 lncRNAs may be mainly involved in metabolism-related pathways, phosphatidylinositol signaling system, p53 signaling pathway, and notch signaling pathway. CONCLUSIONS: Our study demonstrated the potential clinical implication of the 9-lncRNA signature for survival prediction of LUSC patients.
Keywords: Biomarker, long non-coding RNA, lung squamous cell carcinoma, prognosis
DOI: 10.3233/CBM-182275
Journal: Cancer Biomarkers, vol. 26, no. 3, pp. 239-247, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl